Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Toray Industries Inc | 3,765 |
| 2 | Resonac Holdings Corp | 3,264 |
| 3 | Kaneka Corp | 1,630 |
| 4 | Sumitomo Bakelite Co Ltd | 1,588 |
| 5 | Nippon Kayaku Co Ltd | 1,263 |
| 6 | Saudi Arabian Oil Co | 1,203 |
| 7 | Fujifilm Holdings Corp | 1,116 |
| 8 | Nissan Chemical Corp | 1,073 |
| 9 | Mitsui Chemicals Inc | 960 |
| 10 | Toyobo Co Ltd | 933 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C08G | Polymers from non-vinyl bonds (e.g. polyamides, polyesters) | 27,888 |
| 2 | C08L | Polymer compositions (blends) | 23,986 |
| 3 | A61K | Medicinal preparations | 21,740 |
| 4 | A61P | Therapeutic activity (drug indications) | 19,725 |
| 5 | C08K | Polymer compositions (additives) | 13,578 |
| 6 | C08J | Working-up of plastics | 12,022 |
| 7 | Y10T | Cross-reference (technical subjects) | 8,425 |
| 8 | C07D | Heterocyclic compounds | 8,202 |
| 9 | C09D | Coatings, paints, varnishes | 7,296 |
| 10 | B32B | Layered products | 7,243 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Dapsone and promin for the treatment of dementia | 1996 | 29 | |
| COMBINATION OF DAPSONE WITH ADAPALENE | 2011 | AbbVie Inc | 18 |
| DAPSONE TO TREAT ROSASCEA | 2009 | Tolmar Holding Inc | 13 |
| Emulsifying composition containing dapsone | 2007 | 12 | |
| EMULSIVE COMPOSITION CONTAINING DAPSONE | 2005 | Tolmar Holding Inc | 10 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 81 |
| 2017 | 83 |
| 2018 | 87 |
| 2019 | 85 |
| 2020 | 82 |
| 2021 | 63 |
| 2022 | 54 |
| 2023 | 43 |
| 2024 | 41 |
| 2025 | 14 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Michael D. Coleman | Aston University | 21 |
| 2 | Takashi Hashimoto | Kurume University | 17 |
| 3 | R. J. W. Rees | National Institute for Medical Research | 17 |
| 4 | Brian Greenwood | MRC Unit the Gambia | 12 |
| 5 | S Balakrishnan | 12 |
| 6 | G Ramu | National JALMA Institute for Leprosy & Other Mycobacterial Diseases | 12 |
| 7 | Paul Fasal | United States Public Health Service | 11 |
| 8 | J. M. H. Pearson | Central Leprosy Teaching & Research Institute | 10 |
| 9 | Pattyn | 10 | |
| 10 | Charles C. Shepard | University of Hawaii System | 10 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Relapsing polychondritis — REPORT OF TEN CASES | 1979 | 640 | Coagulation, Bradykinin, Polyphosphates, and Angioedema |
| PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE? | 1989 | 521 | Malaria Research and Control |
| Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites | 1998 | 519 | Computational Drug Discovery Methods |
| Dapsone and sulfones in dermatology: Overview and update | 2001 | 447 | Drug-Induced Adverse Reactions |
| Clinical Manifestations of AIDS in the Era of Pneumocystis Prophylaxis | 1993 | 412 | Tuberculosis Research and Epidemiology |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Dapsone?
Which organizations hold the most patents related to Dapsone?
What are the most prolific authors publishing research on Dapsone?
What patent applications have been filed for Dapsone formulations and combinations?
How has the patent and paper publication volume changed over recent years?